TheraGen AI
Paris, France· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $50M
Overview
An AI-driven drug discovery company focused on accelerating the development of oncology therapies.
Oncology
Technology Platform
An AI/ML platform that analyzes multi-omic and clinical data to identify novel oncology targets, predict drug response, and optimize clinical development.
Funding History
1Total raised:$50M
Public Offering$50M
Opportunities
Partnerships with large pharma to augment their oncology pipelines could provide significant non-dilutive funding and validation.
Risk Factors
The 'black box' nature of some AI models can create regulatory and adoption hurdles, and the technology must prove it can consistently deliver clinical candidates.
Competitive Landscape
Competes in the global AI-drug discovery arena, where success requires demonstrating tangible improvements in R&D productivity over traditional methods.